Home
October 2008 November 2008 December 2008
Su Mo Tu We Th Fr Sa
Week 44 1
Week 45 2 3 4 5 6 7 8
Week 46 9 10 11 12 13 14 15
Week 47 16 17 18 19 20 21 22
Week 48 23 24 25 26 27 28 29
Week 49 30

EDAP Launches Enhanced Web Site Show Comments PDF Print E-mail
  
Thursday, 31 July 2008

LYON, FRANCE (Press Release) - July 31, 2008 - EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today the launch of an enhanced Web site containing expanded and user-friendly features based on best practices within the healthcare industry. Visitors can access the new site at www.edap-tms.com.

The upgraded site provides visitors with easier access to the Company's full range of HIFU and lithotripsy products and services. The site also offers new self-service features and improved navigation, including an event-centric stock chart, a download library and contact information for specific inquiries.

Marc Oczachowski, EDAP's Chief Executive Officer stated, "This enhanced Web site accomplishes our goal to create a single, worldwide online resource that centralizes our communication strategies dedicated to our customers, patients, investors and partners. In addition to assisting visitors in obtaining data on our innovative and minimally invasive solutions, it also refers viewers to EDAP's comprehensive educational web sites: www.hifu-planet.com, www.pcaresearch.com and Urotoday's informative site www.urotoday.com/HIFU."

About EDAP TMS SA

EDAP TMS SA develops and markets Ablatherm, the most advanced and clinically proven choice for high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Approved in Europe as a treatment for prostate cancer, Ablatherm-HIFU (High Intensity Focused Ultrasound) is currently undergoing evaluation in a multicenter U.S. Phase II/III clinical trial under an Investigational Device Exemption granted by the FDA. The Company also is developing this technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and commercializes medical equipment for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the company, please visit http://www.edap-tms.com, http://www.hifu-planet.com and http://www.pcaresearch.com or http://www.urotoday.com/HIFU.

EDAP TMS SA

[ PRESS RELEASE ]

Reader Comments

Please log-in or register in order to submit comments.

Powered by AkoComment!

 
User Rating: / 1
PoorBest


 
Visitor Ratings:
Healthcare Professionals:
2 (1 votes)